SCHEMBL4495841

SCHEMBL4495841

c1ccc2c(c1)nc1c3cccoc3ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 1/20 0.42
RIPK1 Q13546 1/20 0.42
ADORA2A P29274 1/20 0.41
KDM4E B2RXH2 5/20 0.41
ALDH1A1 P00352 4/20 0.41
HPGD P15428 4/20 0.41
ELANE P08246 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MYC P01106 1/20 0.40
MAX P61244 1/20 0.40
TDP1 Q9NUW8 4/20 0.39
HSD17B10 Q99714 3/20 0.39
POLB P06746 3/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
KMT2A Q03164 3/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39
MEN1 O00255 2/20 0.39
MAPT P10636 2/20 0.39
RECQL P46063 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29588824 1.00 MAPK10 (0.42) MAPK10RIPK1ADORA2AKDM4EALDH1A1
SCHEMBL27222336 0.91 ADORA2A (0.39) MAPK10RIPK1ADORA2AKDM4EALDH1A1
SCHEMBL6708105 0.87 ALDH1A1 (0.43) ADORA2AKDM4EALDH1A1HPGDELANE
SCHEMBL3295735 0.79 ALDH1A1 (0.37) ADORA2AKDM4EALDH1A1HPGDELANE
SCHEMBL4499241 0.77 MAPK10 (0.45) MAPK10RIPK1ADORA2AKDM4EALDH1A1
SCHEMBL5229303 0.76 KDM4E (0.40) KDM4EALDH1A1HPGDELANENPSR1
SCHEMBL4501863 0.75 CDK4 (0.44) ADORA2AKDM4EALDH1A1HPGDELANE
SCHEMBL5407353 0.75 POLB (0.44) KDM4EALDH1A1TDP1POLBL3MBTL1
Cinnamic Acid SCHEMBL5806210 0.74 HCAR2 (0.43) KDM4EALDH1A1ELANEPOLBL3MBTL1
SCHEMBL29957486 0.73 MAPT (0.41) MAPK10KDM4EALDH1A1HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240167081-A1 IMMOBILIZATION METHODS AND COMPOSITIONS FOR IN SITU DETECTION 10X GENOMICS, INC. 2024-05-23 US claimed
WO-2024102736-A1 IMMOBILIZATION METHODS AND COMPOSITIONS FOR IN SITU DETECTION 10X GENOMICS, INC. (US) 2024-05-16 WO claimed
EP-4363611-A1 COMPOSITIONS AND METHODS FOR ENRICHMENT OF NUCLEIC ACIDS USING LIGHT-MEDIATED CROSS-LINKING Dana-Farber Cancer Institute, Inc. (US) 2024-05-08 EP claimed
CN-117700419-A Nitric oxide donor carbazole derivatives and their use in the treatment of neoplastic diseases 中国医学科学院药物研究所 2024-03-15 CN claimed
CN-114685519-B Pyranocarbazole alkaloid derivatives and application thereof in treating Alzheimer's disease 中国医学科学院药物研究所 2023-09-26 CN claimed
CN-113214275-B Pyranocarbazole alkaloid derivative and application thereof in treating nervous system diseases 中国医学科学院药物研究所 2023-09-26 CN claimed
WO-2023278704-A1 COMPOSITIONS AND METHODS FOR ENRICHMENT OF NUCLEIC ACIDS USING LIGHT-MEDIATED CROSS-LINKING DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-01-05 WO claimed
US-20220372570-A1 CONTROLLED CROSSLINKING OF BIOMOLECUES IN SITU 10X GENOMICS, INC. 2022-11-24 US claimed
CN-114685519-A Pyrano-carbazole alkaloid derivative and application thereof in treating Alzheimer's disease 中国医学科学院药物研究所 2022-07-01 CN claimed
CN-112961165-B Carbazole benzopyran compound and application thereof 同济大学 2022-02-01 CN claimed
CN-113214275-A Pyranocarbazole alkaloid derivatives and their use for treating nervous system diseases 中国医学科学院药物研究所 2021-08-06 CN claimed
CN-112961165-A Preparation and application of novel carbazole benzopyran compound 同济大学 2021-06-15 CN claimed
WO-2020254672-A1 SPATIAL CHARACTERISATION OF TARGET STRUCTURES IN A SAMPLE THERYCELL GMBH (DE) 2020-12-24 WO claimed
US-20260132458-A1 SYSTEMS AND METHODS FOR NUCLEIC ACID MISMATCH ERROR DETECTION ULTIMA GENOMICS INC (US) 2026-05-14 US disclosed
WO-2026052031-A1 CARBAZOLE DERIVATIVE AND USE THEREOF 中国医学科学院药物研究所 2026-03-12 WO disclosed
CN-121627709-A Carbazole derivative and application thereof 中国医学科学院药物研究所 2026-03-10 CN disclosed
EP-0975624-A1 THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS Takeda Chemical Industries, Ltd. (JP) 2000-02-02 EP disclosed
WO-1998046590-A1 THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-10-22 WO disclosed
US-5620973-A CHOLINESTERASE INHIBITOR; ALZHEIMER*S DISEASE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-04-15 US disclosed
EP-0655451-A1 Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132458-A1 SYSTEMS AND METHODS FOR NUCLEIC ACID MISMATCH ERROR DETECTION UBE2V1, MCTS1, MICA MAPK10 2864/4885RIPK1 4061/4885ADORA2A 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.